Genentech's stock hop

The price of Genentech stock went up yesterday afternoon, closing at $83.14 after climbing 1.9 percent. Perhaps we already are seeing a pharma comeback as the Pfizer-Wyeth merger progresses, and perhaps Genentech stock prices will continue to rise until Roche--or someone else--makes it an offer it cannot refuse.  Report.

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.